Iza-Bren Doubles Median Progression-Free Survival in Phase 3 Lung Cancer Study
SystImmune said parent company Biokin reported positive results from a prespecified interim analysis of the PANKU-Lung01 study, comparing Iza-Bren with chemotherapy in previously treated EGFR-mutated non-small cell lung cancer.